Burnzone

Description

The drug is formulated as a tablet containing the active ingredient insert active ingredient name here. The tablet exhibits insert physical characteristics, e.g., color, shape, size. Inactive ingredients include insert list of inactive ingredients here.

Uses and Indications

This drug is indicated for the temporary relief of pain and itching associated with minor burns, minor cuts, minor scrapes, sunburn, insect bites, rashes, and minor skin irritations.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

For adults and children aged 2 years and older, the recommended application is to the affected area no more than 3 to 4 times daily. It is important to ensure that the application is performed gently and that the area is clean prior to use.

For children under 2 years of age, it is advised to consult a physician before use to determine the appropriate course of action.

Contraindications

Use is contraindicated in or near the eyes. Application in large quantities, especially over raw surfaces or blistered areas, is also contraindicated due to the potential for irritation and adverse effects.

Warnings and Precautions

For external use only. It is imperative that the product is not applied to the eyes, as contact may lead to irritation or other adverse effects.

Healthcare professionals should advise patients to discontinue use and seek medical advice if any of the following occur: an allergic reaction, worsening of the condition, lack of improvement within 7 days, recurrence of symptoms after initial resolution, or the emergence or escalation of redness, irritation, swelling, pain, or other concerning symptoms.

In the event of accidental ingestion, immediate medical assistance should be sought, or the patient should contact a Poison Control Center without delay.

Side Effects

Patients using this product should be aware that it is intended for external use only and must not be applied in or near the eyes. In clinical practice, it is important to monitor for potential adverse reactions. Patients are advised to discontinue use and consult a physician if any of the following occur: an allergic reaction, worsening of the condition, lack of improvement within 7 days, recurrence of symptoms after initial resolution, or the onset of redness, irritation, swelling, pain, or any other concerning symptoms.

In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended. Additionally, caution should be exercised to avoid applying the product in large quantities, especially over raw surfaces or blistered areas, as this may increase the risk of adverse effects.

Drug Interactions

There are no specific drug interactions identified for this medication. Additionally, no laboratory test interactions have been noted in the available data. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug or laboratory test interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Burnzone (pain relieving cream). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 2 years and older may apply the medication to the affected area no more than 3 to 4 times daily. For children under 2 years of age, it is advised to consult a physician prior to use.

Geriatric Use

There is no specific information regarding the use of BURNZONE pain relieving cream in geriatric patients. The prescribing information does not provide details on dosage adjustments, safety concerns, or special precautions for elderly patients. Therefore, healthcare providers should exercise caution when considering the use of this product in individuals aged 65 and older, as the absence of data necessitates careful monitoring and assessment of the patient's response to treatment.

Pregnancy

The safety of this product during pregnancy has not been established. Caution is advised as the effects on pregnancy are not well studied, and no specific information is provided regarding risks to the fetus. There are no specific dosage modifications for pregnant individuals mentioned. It is recommended that healthcare professionals consult a physician before use in pregnant patients or those planning to become pregnant.

Lactation

The safety of this product during lactation has not been established. There is a potential for excretion in breast milk; therefore, caution should be exercised when administering this product to nursing mothers.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the drug insert text regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to individuals with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in these patients to ensure safety and efficacy.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the prescribing information.

Overdosage

In the event of an overdosage, immediate medical intervention is crucial. If the substance is ingested, it is imperative to seek medical assistance or contact a Poison Control Center without delay.

Healthcare professionals should be aware that prompt action can significantly influence the outcome of an overdosage situation. Symptoms may vary depending on the specific substance involved, and monitoring for any adverse effects is essential.

Management of overdosage should include supportive care and symptomatic treatment as necessary. Continuous assessment of the patient's condition is recommended to address any complications that may arise.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in question. Further studies may be necessary to elucidate these aspects of nonclinical toxicology.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the product is swallowed. It is important to instruct patients not to use the product in or near the eyes, as this could lead to irritation or injury.

Patients should be cautioned against using the product in large quantities, especially on raw surfaces or blistered areas, to avoid potential adverse effects. They should be informed to discontinue use and consult a physician if they experience any signs of an allergic reaction.

Additionally, healthcare providers should emphasize that patients must stop using the product and seek medical advice if their condition worsens or does not improve within 7 days. Patients should also be instructed to stop use and consult a physician if symptoms resolve and then return within a few days. Furthermore, if patients notice any redness, irritation, swelling, pain, or other symptoms that begin or increase, they should be advised to stop using the product and seek medical attention.

Finally, it is crucial to remind patients to avoid contact with the eyes while using this product to prevent any complications.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at room temperature, ensuring that it is protected from excessive heat or cold to maintain its integrity and efficacy. Proper handling should be observed to prevent any potential degradation of the product.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Burnzone, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)